Eurogentec

Eurogentec is a Belgian biotechnology supplier and contract manufacturing organization headquartered in Seraing, near Liège. Founded in 1985 as a spin-off from the University of Liège, the company began by commercializing genetic-engineering work and initially investigated a genetically engineered vaccine intended to support fish breeding. It subsequently developed into a specialized provider for research laboratories, diagnostic developers, biotechnology companies, and pharmaceutical manufacturers. The company’s activities span both products and outsourced services. In life-science research, Eurogentec supplies custom and catalog oligonucleotides, DNA and RNA-related materials, peptides, antibodies, polymerases, real-time PCR probes, assay components, fluorescent dyes, quenchers, and proteomics services. Its custom-work model allows customers to commission molecular and protein reagents designed for particular research, analytical, or development programs rather than relying only on standardized catalog products. Eurogentec also operates in regulated manufacturing. Its in-vitro-diagnostics activities include contract production of GMP oligonucleotides and Taq DNA polymerases for molecular-diagnostic applications. Its biomanufacturing business provides process development, technology transfer, formulation, scale-up, and production support for proteins, protein conjugates, plasmids, and bacterial vaccines intended for preclinical, clinical, and commercial use. The company has operated licensed contract-manufacturing facilities in Belgium and has supplied products primarily to European pharmaceutical customers, while also maintaining access to the United States market for at least one commercial protein product under U.S. Food and Drug Administration authorization. Eurogentec expanded through acquisitions and international operations during the late 1990s and 2000s. It acquired Oswel Research Product in the United Kingdom in 1999, adding expertise in chemically modified and complex oligonucleotides and their analogues. In 2002 it acquired Berlin-based Wita Proteomics and established a U.S. office in San Diego for oligonucleotide production. In 2009 it announced the acquisition of AnaSpec, a California proteomics company specializing in peptides, labeled peptides, antibodies, fluorescent dyes, and enzyme-activity assays. Kaneka Corporation acquired a majority stake in Eurogentec in 2010, bringing the company into the Japanese chemicals, pharmaceuticals, and advanced-materials group. The brand is positioned as a technically specialized, quality-focused supplier serving the intersection of research, diagnostics, and biopharmaceutical manufacturing. Rather than competing primarily as a consumer-facing biotechnology brand, Eurogentec functions as an infrastructure and services partner whose capabilities can be embedded in customers’ laboratory workflows, diagnostic products, clinical programs, and pharmaceutical supply chains. Its operations have included quality systems and manufacturing environments aligned with European and U.S. regulatory expectations, including ISO 13485 certification for in-vitro-diagnostics oligonucleotide activities. Eurogentec also participated in development work on Bilhvax, a vaccine candidate for schistosomiasis, with INSERM and Pasteur Institute researchers. The available reference material does not establish a current product portfolio, leadership roster, financial profile, or independent listed-company status.

Eurogentec was established in 1985 by University of Liège professors Joseph Martial and André Renard. Martial had studied genetic engineering at the University of California, San Francisco, before returning to Europe and helping commercialize genetic-engineering research associated with the University of Liège. The new company initially worked from university laboratories and pursued a genetically engineered vaccine intended to improve fish breeding. This early project gave the business a practical route into biotechnology commercialization, although the company later became better known for research products and outsourced manufacturing than for a standalone agricultural-vaccine franchise. In 1987, Eurogentec began distributing oligonucleotides to research laboratories. The company’s initial years were difficult, but its commercial direction strengthened in the early 1990s after Jean-Pierre Delwart, an economist educated at Brussels University, joined the business. Eurogentec gradually developed from a university spin-off into a supplier serving biotechnology researchers and pharmaceutical organizations. Its activities broadened from reagent distribution into custom synthesis, molecular-biology support, and contract research. A major transition occurred in 1996, when Eurogentec became a contract research organization for the biopharmaceutical sector. It collaborated with SmithKline Beecham Biologicals in Rixensart, Belgium, on recombinant-protein production for Phase I, Phase II, and Phase III clinical trials. This work connected Eurogentec’s research capabilities with the regulated development pathway of biopharmaceutical products. At the same time, the company expanded its service role for biotechnology companies and universities, complementing its pharmaceutical manufacturing activities with laboratory-oriented products and custom projects. International expansion followed. In 1999, Eurogentec acquired Oswel Research Product in Southampton, United Kingdom. Oswel specialized in chemically modified and complex oligonucleotides and their analogues, including DNA, RNA, and peptide nucleic acid products. In 2002, Eurogentec acquired Wita Proteomics, a Berlin-based company focused on proteomics services. That year it also established a U.S. office in San Diego for oligonucleotide production, giving the business a direct North American presence. In 2004, Eurogentec opened new oligonucleotide- and peptide-synthesis laboratories at the Liège Science Park. The facility was described as incorporating energy-saving and automated building features, reflecting the company’s effort to expand production infrastructure alongside its service portfolio. Between 2000 and 2008, Eurogentec intensified its commercial relationships and signed agreements with companies including Cepheid, Epoch Biosciences, Exiqon, Delphi, and In Cell Art. These relationships supported its position as a specialist supplier and development partner in genomics and molecular biology. Regulated diagnostics became increasingly important during the 2000s. In 2007, Eurogentec expanded its existing GMP facility in Liège to meet stringent manufacturing requirements for oligonucleotides used in in-vitro diagnostics. In 2008, the Liège operation received ISO 13485 certification covering the production and sale of IVD oligonucleotides. Eurogentec’s U.S. operation subsequently received ISO 13485 certification for oligonucleotide diagnostic manufacturing. These steps reinforced the distinction between the company’s research-products business and its quality-controlled manufacturing activities for diagnostic applications. The company continued its proteomics expansion in 2009 by announcing the acquisition of AnaSpec, a privately held biotechnology company based in Fremont, California. AnaSpec added capabilities in peptide synthesis, labeled peptides, antibodies, fluorescent dyes, and enzyme-activity assays. In 2010, Kaneka Corporation acquired a majority stake in Eurogentec. The transaction placed Eurogentec within a diversified Japanese industrial and life-sciences group whose businesses include chemicals, pharmaceuticals, medical devices, and related materials. By 2012, Eurogentec had started commercial manufacturing of a biopharmaceutical for the U.S. market. Its business was organized around three connected areas: life-science research products and services; in-vitro-diagnostics manufacturing solutions; and GMP biomanufacturing. The latter included process development, technology transfer, formulation, scale-up, and manufacture of proteins, protein conjugates, plasmids, and bacterial vaccines for preclinical, clinical, and commercial programs. Eurogentec also participated in development of Bilhvax, a schistosomiasis vaccine candidate, with INSERM and researchers from the Pasteur Institute; the candidate was reported to be entering Phase III trials in 2014. The available sources do not provide a sufficiently detailed current account of Eurogentec’s independent financial performance, current executives, or present-day product status.

• 2012

  Commercial biopharmaceutical manufacturing begins for the U.S. market

  [1]Eurogentecen.wikipedia.org

  Eurogentec started commercial manufacturing of a biopharmaceutical intended for the United States.

• 2010

  Kaneka takes a majority stake

  [1]Eurogentecen.wikipedia.org

  Kaneka Corporation acquired majority ownership of Eurogentec.

• 2009

  AnaSpec acquisition announced

  [1]Eurogentecen.wikipedia.org

  The acquisition added U.S. proteomics capabilities, including peptide, antibody, dye, and enzyme-assay expertise.

• 2008

  ISO 13485 certification for IVD oligonucleotides

  [1]Eurogentecen.wikipedia.org

  Eurogentec received ISO 13485 certification for its Liège-based IVD oligonucleotide production and sales activities.

• 2004

  New Liège synthesis laboratories open

  [1]Eurogentecen.wikipedia.org

  The company opened new production laboratories for oligonucleotide and peptide synthesis at Liège Science Park.

• 2002

  Proteomics and U.S. expansion

  [1]Eurogentecen.wikipedia.org

  Eurogentec acquired Wita Proteomics in Germany and established a San Diego operation for oligonucleotide production.

• 1999

  Acquisition of Oswel Research Product

  [1]Eurogentecen.wikipedia.org

  The acquisition expanded Eurogentec’s capabilities in complex and chemically modified oligonucleotides.

• 1996

  Entry into biopharmaceutical contract research

  [1]Eurogentecen.wikipedia.org

  The company became a contract research organization and collaborated with SmithKline Beecham Biologicals on recombinant proteins for clinical trials.

• 1987

  Oligonucleotide distribution begins

  [1]Eurogentecen.wikipedia.org

  Eurogentec began distributing oligonucleotides to research laboratories, establishing a core life-science-products activity.

• 1985

  Eurogentec is founded as a University of Liège spin-off

  [1]Eurogentecen.wikipedia.org

  Joseph Martial and André Renard established Eurogentec and initially operated from University of Liège laboratories.

Specialized supplier and contract-development and manufacturing partner for life-science research, molecular diagnostics, and biopharmaceutical development.

• Genomics and molecular biology · 1987

  Oligonucleotides

  Eurogentec’s oligonucleotide activity includes research-use and custom DNA and RNA products, as well as chemically modified and complex oligonucleotides. These materials support molecular biology, gene-expression analysis, assay development, sequencing-related workflows, and molecular diagnostics. The company also developed GMP manufacturing capabilities for oligonucleotides used in regulated diagnostic applications.

• Proteomics

  Peptides and antibodies

  The proteomics portfolio includes custom peptide synthesis, labeled peptides, antibodies, and related research services. These offerings are intended for life-science laboratories that need specialized reagents for assay development, detection, biochemical studies, and protein research.

• Life-science research products

  Molecular-biology reagents and assay components

  Eurogentec supplies DNA polymerases, Taq polymerases, real-time qPCR probes, assay services, assay kits, fluorescent dyes, and quenchers. These products support amplification, quantitative PCR, molecular detection, and broader genomics workflows in research and diagnostic development.

• Contract manufacturing

  GMP biomanufacturing

  Eurogentec’s GMP biomanufacturing services cover process development, technology transfer, formulation, scale-up, and manufacture. The described capabilities include proteins, protein conjugates, plasmids, and bacterial vaccines for preclinical, clinical, and commercial programs under applicable U.S. and European regulatory expectations.

• Molecular diagnostics · 2007

  In-vitro-diagnostics manufacturing solutions

  The IVD business provides technical and project support for contract production of GMP oligonucleotides and Taq DNA polymerases used in molecular-diagnostic applications. Manufacturing is performed in controlled clean-room environments and is supported by ISO 13485-certified activities described in the reference material.

• 2014Bilhvax vaccine development

  France · Belgium · International public-health and pharmaceutical development

  Eurogentec participated in development of Bilhvax, a vaccine candidate against schistosomiasis, in partnership with INSERM and researchers from the Pasteur Institute.

  Outcome. The candidate was reported in the reference material to be entering Phase III trials in 2014. The sources do not establish subsequent approval or commercial launch.

  Source

• 2010

  Accept majority investment from KanekaM&A

  Background

  Eurogentec required a broader corporate platform to support its biotechnology, manufacturing, and international activities.

  Action taken

  Kaneka Corporation acquired a majority stake in Eurogentec.

  Aftermath

  Eurogentec became part of the Kaneka Group while continuing as a biotechnology and contract-manufacturing business.

  Source

• 2009

  Acquire AnaSpecM&A

  Background

  Eurogentec aimed to deepen its proteomics offering and add U.S.-based capabilities in peptides, antibodies, dyes, and enzyme assays.

  Action taken

  The company announced the acquisition of privately owned AnaSpec in Fremont, California.

  Aftermath

  AnaSpec’s proteomics capabilities complemented Eurogentec’s genomics and custom-reagent activities.

  Source

• 2007

  Expand GMP capacity for molecular diagnosticsStrategy

  Background

  Growing requirements for high-quality oligonucleotides in in-vitro-diagnostic applications created a need for dedicated regulated manufacturing capacity.

  Action taken

  Eurogentec expanded its existing GMP facility in Liège.

  Aftermath

  The expansion supported subsequent ISO 13485 certification for IVD oligonucleotide activities.

  Source

• 2002

  Expand into proteomics through Wita ProteomicsM&A

  Background

  Eurogentec was extending beyond genomics and oligonucleotides into protein-focused research services.

  Action taken

  It acquired Berlin-based Wita Proteomics and also established a San Diego office for oligonucleotide production.

  Aftermath

  The moves added proteomics expertise and a direct U.S. operating presence.

  Source

• 1999

  Acquire Oswel Research ProductM&A

  Background

  Eurogentec sought to expand its specialist oligonucleotide capabilities, particularly in chemically modified and complex DNA, RNA, and PNA products.

  Action taken

  The company acquired Oswel Research Product, a biotechnology business based in Southampton, United Kingdom.

  Aftermath

  The transaction broadened Eurogentec’s portfolio in complex oligonucleotide synthesis.

  Source

1. 1Eurogentecen.wikipedia.org